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PreviewsWithout DJ-1,
the D2 Receptor
Doesn’t Play
Dopamine is an essential neuromodulator of the
central nervous system whose activity is mediated
through interaction with membrane receptors. Among
these, the D2 receptor plays a pivotal role in regulat-
ing postsynaptic functions as well as dopamine
synthesis and release from dopaminergic neurons.
Parkinson’s disease and parkinsonism are neurode-
generative diseases of dopaminergic neurons affect-
ing the human brain. These diseases are clinically de-
fined by a decrease in dopamine levels that manifest
as motor impairements. In this issue of Neuron, Gold-
berg et al. report of an exciting link between the loss
of function of DJ-1, a protein associated with familial
parkinsonism, and D2 receptor activity.
Parkinson’s disease is one of the most common human
diseases of the elderly, characterized by a large reduc-
tion of the dopamine levels in the brain. Dopamine (in
humans as well as in animals) has a leading role in the
regulation of important physiological functions, such as
control of movement, motivated behavior, and learning
and memory, in addition to the synthesis and release of
some hormones. Indeed, individuals affected by Par-
kinson’s disease have major impairements in con-
trolling voluntary movements, and they present resting
tremors together with a series of other symptoms that
are correlated to the absence of dopaminergic signal-
ing. Most importantly, postmortem analyses of brains
from Parkinson’s patients have shown a strong reduc-
tion of dopaminergic cells in the ventral mesencepha-
lon. This area of the brain contains one of the most
important dopaminergic nuclei, the substantia nigra
(SN) compacta. Dopaminergic neurons from this area
project to the striatum and form the nigrostriatal path-
way, which controls voluntary movements. The degen-
eration of neurons in this pathway is a hallmark of Par-
kinson’s disease.
The search for the molecular causes of Parkinson’s
disease has been very arduous, since most forms of
the disease are sporadic and do not present familial
links. Of course, sporadic forms might also be gener-
ated by defaults in several other neural circuits that im-
pinge on the normal functioning of the dopaminergic
system. However, recent findings indicate the presence
of some familial forms of parkinsonian syndromes in
familial kindreds from different geographic areas where
a genetic component has been characterized (Bonifati
et al., 2004). These findings have led to several very
interesting studies that delineate genes whose de-fective functions have been proposed to participate in
the genesis of the disease.
The first tantalizing candidate gene found by this
search was α-synuclein, a protein that is largely en-
riched at synapses and whose function is still not com-
pletely understood. The most relevant feature of α-synu-
clein, with respect to the disease, is the presence of
point mutations in the protein that favor its oligomeriza-
tion in insoluble inclusions. In the brains of Parkinson’s
disease affected patients, α-synuclein localizes in Lewy
bodies (LB). LBs are cytoplasmic inclusions of aggre-
gated proteins that are highly characteristic of diseased
neurons in parkinsonian brains.
Later, the isolation of several other genes from loci
that were identified as being present in familial parkin-
sonisms suggested the involvement of several proteins
acting at different cellular levels in the genesis of Par-
kinson’s and associated diseases (Vila and Przedbor-
ski, 2004). These proteins are diverse in structure and
function. Some, like parkin (a ubiquitin E3 ligase), or
UCH-L1 (a protein needed for the maintance of the
ubiquitin neuronal content), are clearly involved in the
ubiquitylation pathway. Two others, Pink-1 and LRRK2/
dardarin, are kinases that might have multiple roles at
different cellular levels. Nonetheless, loss of function or
dysfunction of these genes in humans is correlated with
the degeneration of dopaminergic neurons and parkin-
sonisms. Therefore, dysfunctions of the proteasome
(the cellular machinery involved in the clearance of mis-
folded and toxic proteins in the cells), of mitochondrial
metabolism, and of the response to oxidative stress
have been postulated as likely players in the induction
of the degeneration of dopaminergic neurons.
The identification of these proteins, together with the
genetic evidence of their role in parkinsonisms, has led
to a strong interest in generating animal models of Par-
kinson’s disease—animals bearing transgenes for most
of the mutated forms of these human genes, or lacking
their expression, have been generated. These allow the
evaluation of the cellular and physiological damage
provoked by gain- or loss-of-function mutations. The
results, although less spectacular than what would
have been expected, reveal unsuspected facets of the
cellular processes that are likely to lead to neurodegen-
eration. Indeed, the best example comes from studies
on α-synuclein, where it is clear that overexpression of
the mutated forms of human α-synuclein leads, in mice
and flies, to the formation of insoluble aggregates in
vivo and neuronal defects. Yet, the formation of aggre-
gates in vivo might represent a healthy cellular defense
mechanism for avoiding toxicity. Nonetheless, the
question of why these aggregates form is still open.
Furthermore, the expression pattern of all the pro-
teins identified in human studies is not restricted to do-
paminergic neurons, leaving unanswered the question
of why these neurons are more sensitive to degenera-
tion. One insightful piece of evidence is that dopamine
is a molecule that is readily oxidized—which itself
might provoke neuronal damage through the formation
of free radicals and, therefore, through mechanisms of
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1facilitates the transition of synuclein protofibrils (non-
otoxic) into fibrils, the toxic form present in LB (Rochet
net al., 2004). This might suggest that the metabolism of
fdopamine or its signaling or both play a central role in
sthe degeneration of dopaminergic neurons. Impor-
Dtantly, mice lacking the expression of α-synuclein or
aparkin present dysregulation of dopamine release (Abe-
tliovich et al., 2000; Itier et al., 2003; Goldberg et al.,
b2003).
In this issue of Neuron, a novel study by Goldberg et
wal. (2005) sheds light on the function of DJ-1, a Parkin-
tson’s-associated protein. DJ-1 (Bonifati et al., 2003)
thas been identified through mapping studies and posi-
ltional cloning analyses of the human Park7 locus and
was first reported to be associated with an autosomal-
nrecessive form of early-onset parkinsonism. Interest-
wingly, DJ-1 has been known since 1997 and has been
hshown to be implicated in very diverse functions. In-
tdeed, DJ-1 was previously associated with oncogenic
emechanisms, control of gene transcription, regulation
tof mRNA stability, and with sperm maturation and fertil-
dization. Importantly, DJ-1 was also reported as a sensor
hof oxidative stress (Bonifati et al., 2004).
eThe study by Goldberg et al. has addressed the func-
tion of DJ-1 in vivo through the generation of knockout
e
mice by genetic deletion of exon 2 of the gene. The
m
DJ-1 null mice are healthy and reproduce normally, de-
s
spite the earlier implication of this protein in repro-
a
duction. No reduction of SN dopaminergic neurons was 2
observed in the brains of DJ-1 mutants up to 12 months l
of age, nor did these mice present an increased sensi- m
tivity to paraquat, a highly toxic herbicide that converts d
oxygen to reactive oxygen species, thereby leading to w
the death of dopaminergic neurons. It would be of inter- c
est to know if degeneration would occur in older mice. t
However, Goldberg et al., using an elegant multidiscipli- t
nary approach, show that knocking out the DJ-1 gene m
results in a dopaminergic deficit. The function of the h
nigrostriatal pathway of DJ-1 mutants appears to be i
affected, and these mice are hypokinetic in behavioral o
tests. The phenotype is shown to be dependent on a
reduced release of dopamine in the striatum of DJ-1
null mice. The reduction is due to an increased reup- E
take of dopamine by the dopamine transporter (DAT) in I
the absence of an upregulation of this gene at the
mRNA or protein level. Most importantly, behavioral I
and electrophysiological studies show a blunted re- 1
sponse of dopamine D2 receptor to pharmacological B
challenges. D2 receptors play a key role within the do- F
paminergic system, and this privileged position is re-
lated to their dual function in both the regulation of
postsynaptic signaling and of presynaptic autoreceptor
S
activity which is involved in the control of dopamine
synthesis and release. In DJ-1 null mice, both pre- and A
postsynaptic D2 receptor-mediated functions are greatly C
attenuated. Indeed, both the presynaptic inhibitory a
control of dopaminergic neuron firing and the postsyn- B
aptic striatal induction of LTD are reduced. Strikingly, A
the motor and electrophysiological characteristics of B
DJ-1 null mice share similarities with the previously K
(characterized phenotype of D2 receptor null mice, al-hough in the latter they are more severe (Baik et al.,
995; Usiello et al., 2000). However, D2 receptor mRNA
r protein levels were found to be unaltered in DJ-1
ull as compared to wild-type mice. Thus, loss of DJ-1
unction results in an attenuation of D2-mediated re-
ponses. Importantly, recent clinical studies based on
2-specific agonist treatments show that, in humans,
ctivation of D2 receptor signaling might be protective
o neuronal degeneration in Parkinson’s disease (Gold-
erg et al., 2005, and references therein).
In future studies, it would be interesting to evaluate
hether DJ-1’s effect on D2 receptors is restricted to
he nigrostriatal pathway or whether it also extends to
he other dopaminergic pathways involved in the regu-
ation of reward, memory, and hormonal circuitries.
The next exciting step will be to analyze the mecha-
isms by which DJ-1 impairs D2R-mediated functions
hile enhancing dopamine reuptake. The key issue is
ow these Parkinson-associated proteins might in-
erfere with dopamine release and signaling. Are these
ffects due to physical interactions with elements of
he dopaminergic system? Are these proteins acting at
ifferent levels in dopaminergic neurons, or do they
ave common targets? And finally, what causes degen-
ration?
Importantly, none of the loss-of-function mouse mod-
ls generated to date present degeneration of dopa-
inergic neurons as severe as that observed in Parkin-
on’s disease, indicating that these neurons are still
ble to cope with single deficits (Shen and Cookson,
004). The degeneration observed in humans is very
ikely the final event of a series of defaults in the cellular
achinery of dopaminergic neurons. The analysis of
ouble or triple knockout mice for proteins associated
ith parkinsonisms might simulate the disease more
losely. The finding that DJ-1 is very likely required for
he “normal” function of D2 receptors and that DJ-1
ogether with α-synuclein and parkin modulates dopa-
ine release and uptake is important. This might give
ints about the initiation of a pathological cascade that
nduces neuronal degeneration through the alteration
f dopamine synthesis, storage, release, and signaling.
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